Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingcong Ma

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
International Journal of Surgery (London, England)|December 27, 2024
Patient-reported outcome based symptom management is a better option for early postoperative recovery after breast cancer surgery: a parallel controlled randomized clinical trialWeiwei Wang, Xingcong Ma, Changyou Shan, et al.
Nature Biotechnology|February 5, 2020
Interleukin-23 engineering improves CAR T cell function in solid tumorsXingcong Ma, Peishun Shou, Christof Smith, et al.
Nature Immunology|January 8, 2025
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cellsFeifei Song, Ourania Tsahouridis, Simone Stucchi, et al.
Cancer Cell|February 13, 2019
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T CellsHongwei Du, Koichi Hirabayashi, Sarah Ahn, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
International Journal of Surgery (London, England)|December 27, 2024
Patient-reported outcome based symptom management is a better option for early postoperative recovery after breast cancer surgery: a parallel controlled randomized clinical trialWeiwei Wang, Xingcong Ma, Changyou Shan, et al.
Nature Biotechnology|February 5, 2020
Interleukin-23 engineering improves CAR T cell function in solid tumorsXingcong Ma, Peishun Shou, Christof Smith, et al.
Nature Immunology|January 8, 2025
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cellsFeifei Song, Ourania Tsahouridis, Simone Stucchi, et al.
Cancer Cell|February 13, 2019
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T CellsHongwei Du, Koichi Hirabayashi, Sarah Ahn, et al.
Pageof 3